Genenta Appoints New Directors Cantello, Chung, Sharei, and Wider

May 06, 2024 – Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology enterprise focusing on hematopoietic stem cell-based treatments for solid tumors, recently held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. During this meeting, shareholders approved the appointment of five directors to its Board of Directors, effective immediately. This decision includes four new appointments: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D., and Todd Wider, M.D. Pierluigi Paracchi, the Chief Executive Officer, continues to serve on the Board as Chairman.

Pierluigi Paracchi expressed enthusiasm about the new Board members, stating, “When Luigi Naldini, Ph.D., M.D., and I co-founded Genenta, we always aimed to involve prominent figures in the biotech industry. This new Board will aid Genenta in consolidating our achievements and expanding the impact of our cell therapy for tumors.” The Company also extended gratitude to the previous Board members for their valuable contributions.

John L. Cantello, Ph.D., brings over two decades of experience in the biopharma sector. He has served in leadership roles at GlaxoSmithKline and AstraZeneca, overseeing business development in oncology, respiratory, inflammation, metabolic, and rare diseases. Cantello has a notable track record in closing significant deals exceeding $30 billion in value.

Lauren H. Chung, Ph.D., possesses more than 20 years of experience in healthcare investment management and strategic advisory. As founder and CEO of Minleigh LLC, Chung has advised various entities on global strategic plans, mergers and acquisitions, integration, and compliance. She holds a Ph.D. in Biomedical Sciences from Columbia University Vagelos College of Physicians and Surgeons, an M.B.A. from Columbia Business School, and a B.A. in Biochemistry and Economics from Wellesley College.

Armon R. Sharei, Ph.D., is the founder and CEO of Portal Bio and formerly led SQZ Biotechnologies, a company he took from inception to post-IPO, securing more than $300 million in equity financing and a $1 billion collaboration with Roche. Sharei earned his Ph.D. from the Massachusetts Institute of Technology and completed post-doctoral work at Harvard Medical School.

Todd Wider, M.D., is a co-founder and Board member of Xanadu Bio and has served in various leadership roles within the biotech field. He is an honorary member of the medical staff at Mount Sinai Hospital in New York City. Wider received his M.D. from Columbia University’s Vagelos College of Physicians and Surgeons, where he was a Rudin Fellow, and an A.B. from Princeton University. Todd is also involved in documentary filmmaking through Wider Film Projects.

Genenta Science is dedicated to developing a proprietary hematopoietic stem cell therapy for solid tumor cancers. Their leading product, Temferon™, involves ex-vivo gene transfer to deliver immunomodulatory molecules directly to tumors. Currently, Temferon is being investigated in a phase 1/2a clinical trial for patients with newly diagnosed Glioblastoma Multiforme and an unmethylated MGMT gene promoter. Temferon aims to address significant challenges in immuno-oncology by inducing durable immune responses without systemic toxicity.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!